<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven A Curley, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carlton C Barnett, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eddie K Abdalla, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amit G Singal, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth K Tanabe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 05, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H969399451">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease, which may be related to hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol, and/or nonalcoholic steatohepatitis (NASH), among other causes. It is important to note that HCC can occur in a background of normal liver. (See
         <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">
          "Epidemiology and risk factors for hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p>
         Potentially curative partial hepatectomy is one optimal treatment for HCC, but many patients are not eligible for resection because of extrahepatic disease spread, the anatomical constraints of the intrahepatic tumor, or poor underlying liver function, as reflected by the Child-Pugh classification  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         ) or the Model for End-stage Liver Disease (MELD) score (
         <a class="calc calc_professional" href="/z/d/html/15637.html" rel="external">
          calculator 1
         </a>
         and
         <a class="calc calc_professional" href="/z/d/html/16499.html" rel="external">
          calculator 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1234.html" rel="external">
          "Assessing surgical risk in patients with liver disease", section on 'MELD score and Mayo risk score'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">
          "Model for End-stage Liver Disease (MELD)"
         </a>
         .)
        </p>
        <p>
         Even after a potentially curative resection, liver recurrence rates are significant. This has led to efforts to develop neoadjuvant and adjuvant therapy approaches to improve outcomes, although no clear treatment has emerged to significantly reduce recurrence or improve survival to date.
        </p>
        <p>
         This topic will cover prognosis and neoadjuvant and adjuvant therapy for potentially resectable hepatocellular cancer, as well as post-treatment surveillance. The clinical manifestations and diagnosis of HCC, preoperative evaluation and surgical management, nonsurgical options for local ablation, role of liver transplantation, treatment of advanced disease, and an overview of treatment approaches to HCC are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">
          "Epidemiology and risk factors for hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2487.html" rel="external">
          "Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H969400077">
         <span class="h1">
          IMPORTANCE OF COMPREHENSIVE MULTIDISCIPLINARY CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         A majority of patients with HCC have underlying cirrhosis, which is most often related to chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), alcohol, and/or nonalcoholic steatohepatitis (NASH). Cure of HCV does not eliminate risk for future. Patients who undergo therapy for HCC are at high risk not only for progressive and/or recurrent HCC, but also for liver-related morbidity and mortality. It is important that patients have proper monitoring and assessment of their underlying liver disease, which may have a major impact on long-term survival. Prognostic scoring systems to assess the severity of underlying liver disease in patients undergoing treatment for HCC are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'Staging and prognostic scoring systems'
         </a>
         .)
        </p>
        <p>
         Comprehensive care for patients with cirrhosis includes treatment of the underlying liver disease (eg, antiviral therapy for HBV or HCV), immunization against hepatitis A and HBV (if indicated), and cirrhosis management, including endoscopic screening and treatment for varices. (See
         <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">
          "Epidemiology and risk factors for hepatocellular carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H969400084">
         <span class="h1">
          PREOPERATIVE EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preoperative evaluation for resection of HCC focuses on two main issues: the likelihood of disease being confined to the liver, and whether the anatomical constraints of the intrahepatic tumor and underlying liver function will permit resection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anatomic delineation of tumor extent is best achieved with dynamic multiphase computed tomography (CT; in which nonenhanced, hepatic arterial phase and portal venous/delayed phase are assessed separately) or magnetic resonance imaging (MRI) scanning. According to the current (eighth edition, 2017) American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) staging system for HCC  (
         <a class="graphic graphic_table graphicRef110835" href="/z/d/graphic/110835.html" rel="external">
          table 2
         </a>
         ), most consider stages IIIB, IVa, and IVb disease to be incurable by resection. These stages are defined by invasion of a major portal or hepatic vein, direct invasion of organs other than the gallbladder, perforation of the visceral peritoneum, and nodal as well as distant metastases. However, hepatic resection for stages IIIB and IVA disease may be considered in a center of excellence because clinical benefits and long-term survival can be achieved in a properly selected, though admittedly small, minority of patients. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Delineate tumor extent'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A chest CT is recommended to complete the staging evaluation. Although characterized in few reports, the recognized sites of metastatic spread of HCC are lung, bone, peritoneum, adrenals, and lymph nodes. These sites of disease may be demonstrated by standard imaging techniques, but peritoneal disease is frequently missed. (See
         <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">
          "Clinical features and diagnosis of hepatocellular carcinoma", section on 'Extrahepatic metastases'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Less than 10 percent of HCC spontaneously rupture. Although these patients have a high likelihood of peritoneal seeding and usually a poor outcome from resection, this is not inevitable. If bleeding can be controlled, a formal staging evaluation should be undertaken, followed by laparoscopic exploration and subsequent resection, if feasible. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Delineate tumor extent'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients undergoing potentially curative partial hepatectomy for HCC, most perioperative deaths, particularly following major hepatectomy, are due to postoperative liver failure. Degree of liver disease and liver function are the most important predictors of postresection liver failure and death. There are several strategies, including careful patient selection based on overall liver tests, extent of resection to tailored liver function assessed by volumetry and other means (discussed below), and preoperative portal vein embolization (PVE) to produce hypertrophy in the future liver remnant and demonstrate the diseased liver is capable of regeneration, that can mitigate these risks. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Portal vein embolization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Postoperative morbidity and mortality'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Eligible candidates for resection must have a suitable tumor location, adequate liver reserve, and a sufficient liver remnant as assessed by clinical and biochemical measures and, in the case of major hepatectomy, by hepatic volumetry. As a general rule, for patients who would potentially have an insufficient future liver remnant but have preserved liver function and no severe portal hypertension, techniques such as preoperative PVE or transarterial radioembolization (TARE) [
         <a href="#rid1">
          1
         </a>
         ] can initiate hypertrophy of the anticipated future liver remnant to enable a major resection that would not otherwise be possible. Failure of the liver to regenerate sufficiently after PVE is an indication that resection should not be pursued. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Portal vein embolization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H969401849">
         <span class="h1">
          LONG-TERM OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a wide variability in outcomes after resection for HCC, attributable to both tumor-related factors and the underlying liver disease [
         <a href="#rid2">
          2-20
         </a>
         ].
        </p>
        <p>
         Long-term overall survival rates of ≥40 percent can be achieved with limited hepatic resections for small tumors (&lt;5 cm) in patients with Child-Pugh class A cirrhosis  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4,9,12,21
         </a>
         ]. The best outcomes are reported in carefully selected patients who have solitary lesions without intrahepatic metastasis or vascular invasion (gross or microscopic invasion of branches of the portal or hepatic veins), tumor diameter ≤5 cm, and a negative surgical margin of &gt;1 cm; five-year survival rates are as high as 78 percent [
         <a href="#rid3">
          3,11,13,14,17,22
         </a>
         ]. Recent series demonstrate prolonged survival for more advanced HCC with proper patient selection, despite major hepatectomy [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         By contrast, studies with lower long-term survival rates usually include populations of patients with liver dysfunction (Child-Pugh class B or C  (
         <a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">
          table 1
         </a>
         )) or tumors greater than 8 cm in diameter, which require resection of more hepatic parenchyma. These patients have higher operative morbidity and mortality, and their intrinsic liver disease is a major contributor to reduced long-term survival [
         <a href="#rid24">
          24,25
         </a>
         ]. (See
         <a class="local">
          'Underlying liver dysfunction'
         </a>
         below.)
        </p>
        <p>
         Several staging systems have been developed to prognostically stratify outcomes from treatment of HCC. Some, such as the tumor, node, metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC)  (
         <a class="graphic graphic_table graphicRef110835" href="/z/d/graphic/110835.html" rel="external">
          table 2
         </a>
         ), are based entirely upon pathologic disease extent [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         By contrast, other staging systems, such as that of the Barcelona Clinic Liver Cancer (BCLC)  (
         <a class="graphic graphic_figure graphicRef139139" href="/z/d/graphic/139139.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ], Japan Integrated Scoring (JIS) [
         <a href="#rid27">
          27
         </a>
         ], and others [
         <a href="#rid28">
          28-30
         </a>
         ] take underlying liver function into account. There is ongoing debate as to which staging system is optimal for use in HCC patients. Among hepatologists, the BCLC staging classification is the most widely used staging system, but many groups challenge the validity of the system because of good results in selected, higher stage BCLC patients treated with surgery (where BCLC advises nonsurgical therapy) [
         <a href="#rid20">
          20,31-33
         </a>
         ]. More recently, staging systems incorporating expanded surgical indications, such as the Hong Kong Liver Cancer Staging System, have been proposed [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'Choice of staging system'
         </a>
         .)
        </p>
        <p>
         Specific prognostic factors in patients undergoing potentially curative resection are summarized below. A more general discussion about prognostic factors in HCC is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'Other factors influencing survival'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H969401856">
         <span class="h2">
          Tumor-related prognostic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important tumor-related prognostic factors in patients undergoing potentially curative resection of HCC are the presence and degree of vascular invasion, tumor number and size, and surgical margin status:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gross or microscopic invasion of branches of the portal or hepatic veins is associated with a lower probability of survival following resection [
         <a href="#rid3">
          3,35
         </a>
         ]. In one report, there were no three-year survivors among patients with vascular invasion, compared with a 32 percent five-year survival rate in those without vascular invasion [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor size is an important prognostic factor [
         <a href="#rid36">
          36
         </a>
         ]. Both intrahepatic and extrahepatic spread of HCC are more common with tumors &gt;5 cm, particularly when associated with venous invasion [
         <a href="#rid3">
          3,12,37-41
         </a>
         ]. In a report that compared 1000 patients with tumors ≤5 cm and 1366 patients with tumors &gt;5 cm, all of whom underwent hepatectomy over the same period, five-year survival rates were significantly better for patients with smaller tumors (63 versus 37 percent) [
         <a href="#rid41">
          41
         </a>
         ]. Nevertheless, several series indicate five-year survival rates ranging from 19 to 27 percent in selected patients undergoing resection for a single HCC ≥10 cm [
         <a href="#rid24">
          24,42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although increasing tumor size is associated with increased risk for vascular invasion, large solitary tumors without vascular invasion have the same prognosis as small solitary tumors without vascular invasion. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Delineate tumor extent'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The importance of wide resection margins is debated. In a study of 225 patients who underwent resection for HCC, three-year survival was significantly better when a &gt;1 cm tumor-free margin was achieved (77 versus 21 percent, respectively) [
         <a href="#rid7">
          7
         </a>
         ]. However, larger series suggest that a negative margin of &lt;1 cm is acceptable [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other tumor-related poor prognostic indicators in patients undergoing potentially curative hepatectomy are absence of a tumor capsule [
         <a href="#rid15">
          15
         </a>
         ], high preoperative alpha fetoprotein (AFP) levels [
         <a href="#rid45">
          45-51
         </a>
         ], spontaneous tumor bleeding, tumor rupture [
         <a href="#rid52">
          52
         </a>
         ], and poor histologic grade of differentiation [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">
          "Clinical features and diagnosis of hepatocellular carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Delineate tumor extent'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H969401863">
         <span class="h2">
          Underlying liver dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative liver dysfunction and cirrhosis are important negative prognostic factors [
         <a href="#rid12">
          12,20,54
         </a>
         ]. The majority of cases (approximately 80 percent) in the United States and Europe arise in cirrhotic livers. In general, reports of HCC resection in noncirrhotic livers are scarce outside of Asia [
         <a href="#rid12">
          12,55-57
         </a>
         ]. However, outcomes in these noncirrhotic patients appear to be better than those achieved in patients with cirrhosis. In one series of 295 patients undergoing resection of HCC, the four-year survival was more than twofold higher for noncirrhotic compared with cirrhotic patients (81 versus 35 percent) [
         <a href="#rid12">
          12
         </a>
         ]. This difference in outcome is likely related to a higher competing risk of liver-related mortality in patients with cirrhosis, but may also be related in part to the higher frequency of multicentric HCC in patients with cirrhosis.
        </p>
        <p>
         As a general rule, the degree of liver dysfunction (eg, Child-Pugh classification, presence of portal hypertension, ALBI score), rather than the presence of the cancer, limits long-term survival in patients with cirrhosis with small, early stage HCC. (See
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'Staging and prognostic scoring systems'
         </a>
         .)
        </p>
        <p>
         The presence of cirrhosis creates a competing risk of liver-related mortality, and contributes to a higher risk of developing a second primary HCC. These principles were illustrated in one multi-institutional series of 591 patients undergoing resection of HCC, of whom 145 survived longer than five years [
         <a href="#rid40">
          40
         </a>
         ]. While the status of surgical margins, type of resection, preoperative AFP level, and presence of multiple tumors or microscopic vascular invasion were important predictors of five-year survival, they had no bearing on survival beyond five years. However, patients who survived for at least five years had significantly longer survival and cancer-specific survival beyond that point if they had normal underlying liver or minimal periportal fibrosis, rather than underlying cirrhosis. Severe fibrosis/cirrhosis and microscopic vascular invasion have similar increased relative risk for HCC recurrence in multivariable analysis of outcome for resection of HCC [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         In Western countries where HCC is less frequently associated with chronic hepatitis B virus (HBV) infection, five-year survival rates are better (27 to 49 percent) [
         <a href="#rid4">
          4,8,58
         </a>
         ] than they are in locations where HBV is endemic and incidence rates of HCC are high (11 percent or less) [
         <a href="#rid6">
          6,25,59,60
         </a>
         ]. This is likely due to differences in screening rates and the proportion of patients found at early stages, the degree of liver dysfunction and fibrosis, comorbid conditions, and treatment patterns and patient selection for curative treatments, including resection. (See
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'Hepatitis B and C'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'High- versus low-incidence regions'
         </a>
         .)
        </p>
        <p>
         Among patients with cirrhosis related to HBV infection, active hepatitis is also a poor prognostic factor. This was illustrated in a report comparing surgical outcomes in 146 patients with resected HCC and HBV-related Child-Pugh class A or B cirrhosis with those of 155 noncirrhotic patients [
         <a href="#rid39">
          39
         </a>
         ]. Although the prognosis after resection of tumors &lt;5 cm in patients with compensated HBV-related cirrhosis was comparable to that of noncirrhotic patients, the outcome was less favorable in those with underlying active hepatitis, as indicated by a preoperative serum aspartate aminotransferase level &gt;100 international units/L (median survival 10 versus 51 months for those with serum aspartate aminotransferase &gt;100 versus ≤100 international units/L, respectively). Nomograms have been developed to predict survival after resection in Asian populations with HBV-related HCC that include effect of positivity for hepatitis B e antigen (HBeAg), a marker of HBV replication [
         <a href="#rid61">
          61
         </a>
         ]. Whether this nomogram is useful in Western populations is unclear. (See
         <a class="medical medical_review" href="/z/d/html/1234.html" rel="external">
          "Assessing surgical risk in patients with liver disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">
          "Hepatitis B virus: Screening and diagnosis in adults", section on 'Hepatitis B e antigen and antibody'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'Hepatitis B and C'
         </a>
         .)
        </p>
        <p>
         Effective antiviral therapy (ideally before resection) is an important aspect of optimizing outcomes in patients with HBV-related HCC [
         <a href="#rid62">
          62
         </a>
         ]. The benefit of postoperative antiviral therapy after potentially curative resection of HBV-related HCC is addressed below. (See
         <a class="local">
          'HBV-related HCC and nucleoside/nucleotide analogs'
         </a>
         below.)
        </p>
        <p>
         Hepatitis C virus (HCV) infection may be a negative prognostic factor; in several reports, HCV-infected patients fare worse after liver resection than do HBV-infected patients [
         <a href="#rid63">
          63-66
         </a>
         ], though some data suggest that liver and tumor factors overcome viral type as prognostic factors (HCV is associated with a higher incidence of fibrosis, HBV is associated with a higher incidence of larger tumors with vascular invasion) [
         <a href="#rid67">
          67
         </a>
         ]. Hepatologists frequently recommend HCC treatment before HCV therapy in patients with well compensated liver disease due to concern that direct-acting antiviral agents may induce progression, though this is disputed. (See
         <a class="local">
          'HCV-related HCC'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'Hepatitis B and C'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H969401870">
         <span class="h2">
          Patterns of relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of recurrences are intrahepatic and may reflect local recurrence or a new second primary tumor [
         <a href="#rid68">
          68-71
         </a>
         ]. Late recurrences (ie, beyond two years) are more likely to represent a de novo second primary tumor [
         <a href="#rid72">
          72,73
         </a>
         ]. Fewer than 20 percent of disease recurrences have an extrahepatic component, which may present simultaneously with or develop after an intrahepatic recurrence or represent the only site of disease recurrence [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H854690057">
         <span class="h2">
          Management of relapsed disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with isolated local recurrence, several effective treatment modalities can provide disease control, including repeat hepatectomy [
         <a href="#rid75">
          75-79
         </a>
         ], thermal ablation, liver transplantation, and transarterial chemoembolization or radioembolization. (See
         <a class="medical medical_review" href="/z/d/html/15589.html" rel="external">
          "Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2487.html" rel="external">
          "Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p>
         Patients with extrahepatic spread have a poor prognosis overall and are best treated with systemic therapy. (See
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H969401877">
         <span class="h1">
          NEOADJUVANT THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the high rates of local recurrence after hepatic resection, several types of locoregional neoadjuvant therapy have been evaluated prior to resection. Given the lack of survival benefit in most studies, and the heterogeneity of the populations that have been studied using these approaches, we suggest not pursuing neoadjuvant therapy prior to hepatic resection, unless in the context of a clinical trial.
        </p>
        <p>
         Despite potentially curative surgery, local recurrence develops in most patients. It is believed that many recurrences do not arise because of inadequate surgical resection but because of preexisting, clinically occult, microscopic tumor foci, thus providing the impetus to evaluate neoadjuvant therapies to eradicate this disease prior to definitive resection.
        </p>
        <p>
         Various approaches to neoadjuvant therapy have been evaluated, including systemic chemotherapy [
         <a href="#rid80">
          80
         </a>
         ], regional approaches (TACE [
         <a href="#rid81">
          81-88
         </a>
         ], hepatic artery infusion of radiolabeled lipiodol [
         <a href="#rid89">
          89
         </a>
         ], transarterial infusional chemotherapy alone [
         <a href="#rid90">
          90
         </a>
         ], and regional irradiation with or without chemotherapy or TACE [
         <a href="#rid91">
          91-93
         </a>
         ]), and immunotherapy-based regimens [
         <a href="#rid94">
          94
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2487.html" rel="external">
          "Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"
         </a>
         .)
        </p>
        <p>
         Although many of these therapies can decrease tumor size, this has not translated into a survival benefit in most studies. In addition, the small size of many studies, the relative paucity of randomized controlled trials, and the heterogeneity in the patient populations under study limit the generalizability of the results, and the ability to interpret and compare data. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TACE followed by portal vein embolization (PVE) has been proposed as an approach to prepare for major hepatectomy in patients with and without cirrhosis with preserved liver function and minimal portal hypertension. At least some data suggest better tumor control, very low surgical morbidity and mortality, and favorable long-term outcomes, although there are no randomized trials with a surgery alone or PVE alone control group [
         <a href="#rid23">
          23,95-97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Furthermore, a number of uncontrolled series and at least one randomized controlled trial have suggested that TACE used prior to an attempt at resection is associated with worse survival [
         <a href="#rid83">
          83-86,88
         </a>
         ]. In a randomized controlled trial, 52 patients with resectable, large HCC were randomly assigned to preoperative TACE (one to five courses) or surgery without delay [
         <a href="#rid86">
          86
         </a>
         ]. Patients randomized to TACE had a slightly longer operative time and a higher rate of concomitant resection of adjacent organs. Despite similar disease-free survival in the two groups, the incidence of extrahepatic cancer was higher in those who had been treated with TACE (57 versus 23 percent), and the actuarial survival rate was significantly worse in this group. The delay in surgical treatment may have contributed to this detrimental impact on survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of TACE as a nonsurgical therapy for localized HCC, including its use in patients awaiting orthotopic liver transplantation for HCC (termed "bridging therapy"), is discussed in further detail elsewhere, as is the role of PVE, with or without TACE, prior to resection of HCC. (See
         <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">
          "Liver transplantation for hepatocellular carcinoma", section on 'Chemoembolization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Portal vein embolization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with resectable HCC and portal vein tumor thrombus (PVTT), at least one randomized trial suggests better postoperative survival among Chinese patients who receive neoadjuvant three-dimensional conformal radiation therapy (3D-CRT) [
         <a href="#rid93">
          93
         </a>
         ]. In this multicenter trial, in which all 164 enrolled patients had hepatitis B virus (HBV)-associated HCC, patients with potentially resectable HCC and right- or left-side branch or main portal vein thrombus of Cheng type II or III [
         <a href="#rid98">
          98
         </a>
         ] were administered radiation therapy (RT) at a dose of 18 Gy in daily 3 Gy fractions, with treatments administered five days per week. Of note, approximately 83 percent of patients did not have cirrhosis. They grouped noncirrhotic patients with Child-Pugh A cirrhotics. Patients receiving RT were reevaluated four weeks after completion of RT, and surgery was carried out within five days in the absence of a contraindication to surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A partial remission (as defined by any downstaging in the Cheng classification or any conspicuous restoration of blood flow in the portal vein) was achieved by 21 percent of patients within four weeks of RT. Seven patients had disease progression after RT and two developed grade 3 liver toxicity that rendered them unsuitable for subsequent hepatic resection. At a median follow-up of 15.2 months, overall survival rates were superior in the RT group (89, 75, 44, and 27 percent at 6, 12, 18, and 24 months; corresponding rates with surgery alone were 82, 43, 17, and 9 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our view, this single trial is not adequate to recommend routine neoadjuvant RT prior to resection of HCC with or without major PVTT for several reasons:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The population under study in this trial was unique, and it is not clear whether the results are generalizable to other populations. Western guidelines, including those based on the classification  (
         <a class="graphic graphic_figure graphicRef139139" href="/z/d/graphic/139139.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ], consider HCC with portal vein tumor thrombus to represent advanced, incurable cancer for which systemic therapy alone is advised. Surgery is more frequently adopted in China and Southeast Asia, where the majority of patients (as in this trial) have HBV-associated HCC and better liver function reserves and long-term survival outcomes after hepatectomy, in comparison with patients in Europe, North America, and Japan, where hepatitis C virus (HCV) infection and nonalcoholic steatohepatitis (NASH) predominate [
         <a href="#rid99">
          99,100
         </a>
         ]. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma", section on 'Patients with portal vein tumor thrombus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Much larger trials with patients who have other causes of HCC, including chronic HCV infection, alcoholic cirrhosis, and NASH, are needed before adopting routine use of neoadjuvant therapy. (See
         <a class="medical medical_review" href="/z/d/html/2476.html" rel="external">
          "Staging and prognostic factors in hepatocellular carcinoma", section on 'Hepatitis B and C'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         It is not known whether this is the optimal dose and number of fractions to treat HCC with PVTT. Rigorous trials to optimize external beam irradiation are needed to determine maximizing response while minimizing toxicity (particularly since small variations in the delivery of RT can significantly impact resection risk due to radiation-induced changes in the hepatic parenchyma).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In our view, more extensive confirmatory work is completed and reported. Whether other locoregional treatment methods, such as transarterial radioembolization, which appears effective in patients with PVTT, may serve as a better neoadjuvant approach to resection in patients with PVTT has not been studied. (See
         <a class="medical medical_review" href="/z/d/html/15589.html" rel="external">
          "Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation", section on 'Patients with large intrahepatic tumor volume or PVTT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H969401884">
         <span class="h1">
          POSTOPERATIVE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The high recurrence rate following curative resection for HCC has prompted a search for effective postoperative (adjuvant) therapies. For patients with HCC, the goals of postoperative therapy are to eliminate residual neoplastic cells and prevent recurrent HCC (ie, secondary chemoprevention).
        </p>
        <p>
         Adjuvant antiviral therapy improves overall survival outcomes after potentially curative treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV)-related HCC and is recommended for those with active viral infection. The use of other adjuvant therapies following potentially curative resection of HCC is not established and remains investigational. Patients interested in these approaches are encouraged to enroll on clinical trials, where available. This position is consistent with clinical guidelines from the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid101">
          101-103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H969401914">
         <span class="h2">
          Antiviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjuvant antiviral therapy improves outcomes after potentially curative treatment of HBV-related HCC. For patients with HBV-related HCC and active HBV-related liver disease, we recommend the use of nucleos(t)ide analogs. The benefits of nucleos(t)ide analogs on oncologic outcomes in resected patients who do not have active hepatitis and/or a high viral load remain uncertain and require confirmation in large controlled trials with adequate follow-up before this approach can be widely adopted.
        </p>
        <p>
         The chemopreventive benefits of antiviral therapy, particularly with direct-acting antiviral (DAA) agents, after resection of HCV-related HCC are less certain. Nevertheless, for those with active viral infection, treatment is indicated to attempt to diminish liver morbidity and mortality. Some postulate that DAA post-treatment may be associated with early recurrence, though this is disputed. (See
         <a class="local">
          'HCV-related HCC'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H82761845">
         <span class="h3">
          HBV-related HCC and nucleoside/nucleotide analogs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), higher viral load (serum HBV DNA of &gt;10
         <sup>
          6
         </sup>
         copies/mL) has been associated with higher rates of recurrence after resection, particularly late recurrence (which is more likely to represent a de novo second primary tumor rather than metastasis from the primary HCC) [
         <a href="#rid104">
          104,105
         </a>
         ].
        </p>
        <p>
         Treatment with nucleos(t)ide analogs can reduce the risk of recurrence and improve the prognosis of HBV-related HCC after curative therapy. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management"
         </a>
         .)
        </p>
        <p>
         The association between nucleos(t)ide analog use and outcomes after resection in patients with HBV-related HCC has been addressed in multiple cohort studies, two randomized controlled trials, and two meta-analyses:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefits of nucleos(t)ide analogs on prognosis of HBV-related, surgically treated HCC were directly addressed in a randomized trial in which 180 patients with previously untreated, HBV-related, potentially resectable HCC, without HCV coinfection, with Child-Pugh A or B cirrhosis and a preoperative serum HBV DNA load of more than 500 copies/mL were randomly assigned to postoperative antiviral therapy (
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         100 mg daily, starting within one week of surgery;
         <a class="drug drug_general" data-topicid="8690" href="/z/d/drug information/8690.html" rel="external">
          adefovir
         </a>
         or
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         were used for patients who were drug resistant) or control [
         <a href="#rid106">
          106
         </a>
         ]. At a median follow-up of 40 months, patients assigned to antiviral therapy had significantly better two-year overall (94 versus 62 percent) and recurrence-free survival (56 versus 20 percent). No adverse effects caused by antiviral treatment were reported, except one patient treated with lamivudine plus adefovir dipivoxil developed transient anorexia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Interpretation of these data is limited by imbalances in the study arms that favored better outcomes in the antiviral group (smaller tumor burden, smaller proportion of incomplete or no tumor encapsulation, lower levels of serum alpha-fetoprotein [AFP], fewer poorly differentiated tumors, and lower Barcelona Clinic Liver Cancer [BCLC] stage).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benefit was also suggested in a second randomized trial in which 200 patients undergoing complete (R0) resection for HBV-related HCC who had not previously received antiviral treatment and who had an HBV DNA level of more than 2000 international unites/mL were randomly assigned to
         <a class="drug drug_general" data-topicid="8690" href="/z/d/drug information/8690.html" rel="external">
          adefovir
         </a>
         (100 mg daily, continued until unacceptable toxicity or withdrawal of consent) or no treatment [
         <a href="#rid107">
          107
         </a>
         ]. At five-year follow-up, overall survival was significantly better in the group receiving antiviral therapy (adjusted hazard ratio [HR] 0.42, 95% CI 0.271-0.651). Antiviral therapy was an independent prognostic factor for late recurrences (HR 0.348, 95% CI 0.177-0.687) but not recurrence within two years of resection (HR 0.949, 95% CI 0.617-1.459).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of 13 cohort studies of HBV-related HCC and one of the two randomized controlled trials described above [
         <a href="#rid106">
          106
         </a>
         ] totaling 6350 patients (1227 treated with and 5123 without antiviral treatment) concluded that nucleos(t)ide analog treatment could significantly reduce the risk of HCC recurrence by 34 percent after curative treatment and diminished overall mortality (HR for death 0.56, 95% CI 0.43-0.73) [
         <a href="#rid108">
          108
         </a>
         ]. Notably, the impact of HBV viral load was not addressed; the randomized controlled trial only included patients with HBV DNA of more than 500 copies/mL, while the cohort studies mostly did not include information on the percentage of patients who had a detectable viral load. The available data suggested no serious adverse events attributed to therapy.
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          Lamivudine
         </a>
         resistance developed in 29 to 38 percent of treated patients but could be "rescued" by alternative forms of antiviral therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The validity of the results is limited by the quality of the available data (particularly that derived from a large nationwide cohort study of 4569 patients from Taiwan [
         <a href="#rid109">
          109
         </a>
         ], which make up the majority of the patents studied). Data were not available from this database series on the completeness of resection, recurrences were only counted if they required rehospitalization and administration of HCC treatment after the index admission, and there was a potential for survivor bias. Follow-up of the untreated cohort began on the first day after the index admission, while follow-up of the treated cohort began on the day of the first prescription of the nucleos(t)ide analog, which occurred a median of 0.66 years (mean 1.19 years) after resection. Excluding early recurrences, which are less likely to benefit from antiviral therapy, might have amplified the overall survival benefit from nucleos(t)ide therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A later updated meta-analysis of these same 13 cohort studies and both of the randomized controlled trials (totaling 8060 patients) came to the same conclusion: recurrence rates were significantly decreased among those who received treatment (one-year recurrence RR 0.50, 95% CI 0.36-0.68; three-year recurrence RR 0.70, 95% CI 0.56-0.87) [
         <a href="#rid110">
          110
         </a>
         ]. Overall survival was also significantly higher with antiviral treatment (five-year survival RR 1.40, 95% CI 1.24-1.58). Furthermore, when the data from the Taiwanese cohort study were not included, there was still a significant reduction in the risk of recurrence at one year (RR 0.41, 95% CI 0.28-0.61) and three years (RR 0.63, 95% CI 0.43-0.94) attributed to the use of adjuvant nucleos(t)ide therapy. The impact of pretreatment viral load was not addressed.
        </p>
        <p>
        </p>
        <p>
         In our view, these data support a recommendation for nucleos(t)ide therapy after potentially curative therapy in individuals with resected HCC and active HBV-related liver disease (ie, high serum HBV DNA, abnormal transaminases). The benefits of nucleos(t)ide analogs on oncologic outcomes in resected patients who do not have active hepatitis and/or a high viral load remain uncertain and require confirmation in large controlled trials with adequate follow-up before this approach can be widely adopted. The main drawbacks of the long-term use of antiviral therapy are the need for life-long therapy; emergence of drug resistance, although this concern is lower with more recent agents such as tenofovir and
         <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">
          entecavir
         </a>
         ; potential long-term toxicities such as renal dysfunction; and associated costs [
         <a href="#rid111">
          111
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H305136225">
         <span class="h3">
          HCV-related HCC
         </span>
        </p>
        <p class="headingAnchor" id="H1870727770">
         <span class="h4">
          Benefits of antiviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with hepatitis C virus (HCV)-related HCC, we endorse the use of direct-acting antiviral (DAA) agents used for HCV therapy. A major benefit of HCV antiviral treatment among those with active viral infection is a reduction in liver-disease-related morbidity and mortality.
        </p>
        <p>
         The chemopreventive benefits of antiviral therapy after potentially curative resection of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) are debated. The available data suggest decreased recurrences and improved survival with IFN-based HCV therapy, which is no longer recommended for HCV antiviral therapy. There are also some data supporting a survival benefit for DAA agents used for HCV therapy after a complete response to HCC treatment. Whether these benefits are attributable to a reduction in liver-disease-related morbidity/mortality from uncontrolled viremia or truly reflect a decrease in HCC deaths (the goal of a chemopreventive agent) is unclear. Nevertheless, a major benefit of HCV antiviral treatment with DAA agents among those with active viral infection is a reduction in liver-disease-related morbidity and mortality.
        </p>
        <p>
         There are no randomized trials examining the impact of antiviral therapy on outcomes after resection of HCV-related HCC. Historically, HCV sustained viral response (SVR) using IFN-based therapy was associated with significant reductions in HCC recurrence rates after curative treatment. In an analysis of eight studies (totaling 1519 patients) examining the impact of an SVR on outcomes after potentially curative therapy (resection, local ablation), patients who achieved an SVR had significantly improved overall survival (HR 0.18, 95% CI 0.11-0.29) and better relapse-free survival (HR 0.5, 95% CI 0.40-0.63) than those who did not achieve SVR [
         <a href="#rid112">
          112
         </a>
         ]. However, all included studies used IFN-based therapy, which is no longer recommended for HCV antiviral therapy.
        </p>
        <p>
         DAA agents offer increased tolerability and a higher level of viral eradication. Similar to IFN-based therapy, DAAs can reduce the risk of cirrhosis progression and hepatic decompensation in most HCV-infected patients; however, whether the chemopreventive benefits are similar to those of IFN-based antiviral therapy is unclear:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although some observational studies suggested an unexpectedly high risk of early HCC recurrence following DAA therapy, other large studies have not. (See
         <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">
          "Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Hepatocellular carcinoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Support for a potential benefit of DAA therapy was provided by a retrospective, multicenter cohort study of 797 patients with HCV-related HCC who achieved a complete response to initial therapy (resection in 14 percent, local ablation in 34 percent, transarterial chemoembolization (TACE) in 45 percent, or radioembolization/radiation therapy in the remainder) over a four-year period [
         <a href="#rid113">
          113
         </a>
         ]. Overall, 383 (48 percent) received DAA therapy, while 414 (52 percent) did not. The two groups had similar tumor burden at diagnosis. DAA therapy was associated with significantly reduced mortality in both crude (HR 0.37, 95% CI 0.26-0.54) and weighted models (HR 0.54, 95% CI 0.33-0.90). The benefits were greater among patients who underwent resection or ablation than among those who received TACE, and there was a significantly greater DAA benefit among patients who remained recurrence free (HR for death 0.09, 95% CI 0.02-0.29) compared with those who did not (HR 0.86, 95% CI 0.49-1.52). Furthermore, among the DAA-treated patients, those with an SVR had significantly reduced mortality from the time of DAA initiation compared with those without an SVR (HR 0.27, 95% CI 0.13-0.57). In a post hoc analysis, the proportion of deaths that were liver related was significantly lower in DAA-treated patients than in untreated patients (16.3 versus 34 percent, p = 0.03), whereas the proportion of HCC-related deaths was similar between the groups (30.2 versus 29.1 percent). These data suggest that the beneficial effect of DAA treatment was related to improvement in liver dysfunction, rather than a direct chemopreventive effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similar results were also found in a smaller prospective analysis in which 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early HCC who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAAs were compared with a historical cohort of 328 DAA-untreated patients treated for early HCC [
         <a href="#rid114">
          114
         </a>
         ]. Therapy with DAAs significantly improved overall survival (HR 0.39, 95% CI 0.17-0.91), but it did not reduce HCC recurrence rates.
        </p>
        <p>
        </p>
        <p>
         Indications for antiviral therapy in patients with HCV infection, including those with HCC, are addressed separately. (See
         <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">
          "Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1080640563">
         <span class="h4">
          Timing of antiviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         An unresolved issue is the optimal timing of anti-HCV therapy in relation to HCC treatment. At least some data suggest that outcomes are improved regardless of whether a sustained virologic response is achieved before or after hepatectomy [
         <a href="#rid115">
          115
         </a>
         ]. However, data comparing preoperative versus postoperative therapy are extremely limited, and clinical practice is variable, including that of the authors and editors associated with this review.
        </p>
        <p>
         Those who favor treating prior to surgery raise the following issues:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although concern as to whether initiating DAAs prior to surgical treatment of HCC is associated with aggressive progression of the HCC has been raised in small single-institution observational studies [
         <a href="#rid116">
          116-118
         </a>
         ], several large studies have refuted this association [
         <a href="#rid113">
          113,119-121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Many liver surgeons, including some of the authors of this topic review, prefer that untreated HCV patients undergo antiviral treatment with DAAs prior to planned surgery, citing poor hepatic function and renal function after even minimally invasive resection in untreated patients with low viral load and normal liver function tests preoperatively that are not seen in treated patients. There are few published data in this regard.
        </p>
        <p>
        </p>
        <p>
         On the other hand, at some institutions (and consistent with guidelines from the American Gastroenterological Association [AGA] [
         <a href="#rid122">
          122
         </a>
         ] and the NCCN [
         <a href="#rid123">
          123
         </a>
         ]), postoperative therapy is a standard approach for the following reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no urgency to HCV therapy given at least some evidence of similar outcomes regardless of timing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HCV therapy is 8 to 12 weeks, and surgery does not need to be delayed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antiviral therapy can be deferred four to six months to confirm a complete response to HCC therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active HCC may be associated with a lower likelihood of obtaining a sustained viral response to DAAs [
         <a href="#rid124">
          124-127
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In our view, either approach is acceptable.
        </p>
        <p class="headingAnchor" id="H1991516433">
         <span class="h3">
          What is the role of adjuvant interferon?
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of interferon alfa (IFNa) as adjuvant therapy following complete resection of HCC is not established. Although randomized trials suggest that adjuvant IFNa reduces early mortality, there are limited data on long-term survival [
         <a href="#rid128">
          128
         </a>
         ], so it is unclear whether disease recurrence is being delayed or truly prevented with this approach. IFNa is also associated with significant side effects and high rates of patient discontinuation. Furthermore, nucleos(t)ide analogs for HBV are preferred given the need for maintained viral suppression. (See
         <a class="local">
          'HBV-related HCC and nucleoside/nucleotide analogs'
         </a>
         above.)
        </p>
        <p>
         IFN suppresses the replication of HBV and HCV. The benefit of postoperative IFNa (and in one case interferon beta [IFNb] [
         <a href="#rid129">
          129
         </a>
         ]) has been addressed in several randomized controlled clinical trials, most of which were conducted in populations from China and Japan with predominantly hepatitis virus associated HCC [
         <a href="#rid16">
          16,128-136
         </a>
         ]. In a meta-analysis of six trials of postoperative IFN after curative resection of HCC in patients with viral hepatitis [
         <a href="#rid129">
          129,131-133,136
         </a>
         ], adjuvant IFNa significantly decreased early (within two years of surgery) mortality after curative resection for HCC (pooled risk ratio [RR] 0.65, 95% CI 0.52-0.80) [
         <a href="#rid137">
          137
         </a>
         ]. The effect on tumor recurrence was less pronounced but still significant (RR 0.86, 95% CI 0.76-0.97).
        </p>
        <p class="headingAnchor" id="H2275288974">
         <span class="h2">
          Investigational approaches
         </span>
        </p>
        <p class="headingAnchor" id="H3509841459">
         <span class="h3">
          Atezolizumab plus bevacizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with treated hepatocellular carcinoma at high risk for recurrence, the use of adjuvant
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         improved recurrence-free survival (RFS) but increased toxicity in a phase III trial [
         <a href="#rid138">
          138
         </a>
         ]. This approach, while promising, remains investigational. Further follow-up of RFS and overall survival (OS) are necessary to determine whether adjuvant atezolizumab plus bevacizumab delays or truly prevents disease recurrence. Of note, patients with treated hepatocellular carcinoma at low-risk for recurrence should not be offered adjuvant atezolizumab plus bevacizumab since treatment-related toxicities likely outweigh the potential survival benefits.
        </p>
        <p>
         In an international, open-label phase III trial (IMbrave050), 668 patients with Child-Pugh Class A hepatocellular carcinoma and no extrahepatic disease who were at high risk for recurrence after curative intent resection or ablation were randomly assigned to either adjuvant therapy with
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         (1200 mg) plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         (15 mg/kg) administered intravenously every three weeks for one year (17 cycles), or active surveillance [
         <a href="#rid138">
          138
         </a>
         ]. High-risk features were defined as at least one or more of the following: tumor greater than five cm, more than three tumors, microvascular invasion, minor microvascular invasion Vp1/Vp2, or grade 3 or 4 pathology. In over half (63 percent) of patients, HBV infection was the etiology of the HCC. At median follow-up of 17 months, adjuvant therapy improved RFS relative to active surveillance (one-year RFS 78 versus 65 percent; medians not reached for either arm; HR 0.72, 95% CI 0.53-0.98) with similar overall health-related quality of life and functioning. Overall survival data were immature at first interim analysis and not reported. Grade ≥3 toxicities were higher for adjuvant therapy versus surveillance (41 versus 13 percent), including two therapy-related deaths (esophageal varices hemorrhage and ischemic stroke).
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">
          atezolizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         for advanced hepatocellular cancer is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma", section on 'Atezolizumab plus bevacizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3104835177">
         <span class="h3">
          Hepatic arterial infusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of hepatic arterial infusion (HAI; adjuvant chemotherapy administered locoregionally via the hepatic arteries) remains investigational, as data are mixed for the efficacy of this approach. Furthermore, few centers have experience performing percutaneous HAI therapy. (See
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma", section on 'Systemic chemotherapy'
         </a>
         .)
        </p>
        <p>
         Randomized trials initially suggested limited benefit for adjuvant HAI in resected HCC. As an example, in one meta-analysis of three randomized trials, 108 patients with resected HCC received varying adjuvant chemotherapy regimens. Two trials included HAI with
         <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">
          epirubicin
         </a>
         , and one trial used intravenous epirubicin [
         <a href="#rid139">
          139
         </a>
         ]. Relative to resection alone, adjuvant chemotherapy failed to improve disease-free survival or overall survival, and was associated with worse survival outcomes in patients with biopsy-proven cirrhosis.
        </p>
        <p>
         In contrast, a subsequent randomized trial conducted in 315 patients with resected HCC and microvascular invasion evaluated adjuvant HAI using
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         plus
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (FOLFOX) versus observation alone [
         <a href="#rid140">
          140,141
         </a>
         ]. HAI with FOLFOX was infused using a percutaneous approach, without an infusion pump. At median follow-up of approximately two years, relative to observation, HAI with FOLFOX improved disease-free survival (median 20 versus 10 months, HR 0.59, 95% CI 0.43-0.81) but not overall survival [
         <a href="#rid141">
          141
         </a>
         ]. However, this trial was conducted almost exclusively in patients from China with HCC and HBV infection, so the ability to generalize these results to populations in other geographic regions with HCC and no HBV infection is unclear.
        </p>
        <p class="headingAnchor" id="H1149628134">
         <span class="h3">
          Other approaches
         </span>
        </p>
        <p class="headingAnchor" id="H3414113887">
         <span class="h4">
          Transarterial chemoembolization
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is clinical variability in the use of adjuvant TACE following resection of HCC, as studies are inconsistent for the efficacy of this approach. In China, many patients still undergo TACE after hepatic surgery, regardless of the risk profile for recurrence after resection [
         <a href="#rid142">
          142,143
         </a>
         ]. Elsewhere, adjuvant TACE is not standard clinical practice. Further randomized trials are needed to define the appropriate patient populations that may benefit from adjuvant TACE [
         <a href="#rid144">
          144
         </a>
         ].
        </p>
        <p>
         The available data on the benefits of adjuvant TACE following resection are mixed, likely due to tumor biology and patient selection. Some studies suggest little evidence to support this approach [
         <a href="#rid145">
          145-148
         </a>
         ], while other studies suggest some benefit [
         <a href="#rid149">
          149-151
         </a>
         ]. In a randomized phase III trial, adjuvant TACE improved overall survival over no treatment in 280 patients with an HBV-related resected HCC at intermediate or high risk for recurrence (a single tumor &gt;5 cm without macrovascular invasion, a single tumor with macrovascular invasion, or two or three tumors) [
         <a href="#rid151">
          151
         </a>
         ]. In another randomized trial, postoperative TACE did not improve outcomes compared with traditional herbal medicine in 364 patients at low risk for recurrence (resected small HCC &lt;5 cm) [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
         The use of TACE for locoregional HCC that is not amenable to resection or liver transplantation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15589.html" rel="external">
          "Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation", section on 'TACE and bland particle embolization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1282690786">
         <span class="h4">
          Radiolabeled lipiodol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another locoregional approach involves the intra-arterial infusion of 131I-labeled lipiodol. Lipiodol (Laboratoire Guerbet, France) is a stable fatty acid ethyl ester derived from poppy seed oil that is retained within HCC after intra-arterial injection [
         <a href="#rid152">
          152
         </a>
         ]. The benefits of adjuvant radiolabeled lipiodol have been addressed in the following reports:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a trial from Hong Kong in which 43 patients with HCC (mostly related to chronic HBV infection) were randomly assigned to a single dose of 131I-lipiodol or placebo following curative resection, treatment was associated with significantly fewer tumor recurrences (48 versus 64 percent) and significantly higher rates of five-year disease-free and overall survival (67 versus 36 percent) [
         <a href="#rid153">
          153,154
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On the other hand, benefit of a single postoperative injection of lipiodol could not be confirmed in a second trial that randomly assigned 103 patients to resection with or without lipiodol administered four to six weeks later [
         <a href="#rid155">
          155
         </a>
         ]. The small improvement in five-year relapse-free survival in patients receiving lipiodol (45 versus 33 percent, HR 0.75, 95% CI 0.46-1.23) was not statistically significant, and overall survival was similar (54 percent in both groups at five years).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A third randomized trial involving 100 patients has completed accrual and is awaiting data maturation [
         <a href="#rid156">
          156
         </a>
         ]. This approach also needs further evaluation in patients with HCC related to different underlying diseases (such as HCV infection), which may have different tumor biology.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2104379915">
         <span class="h4">
          Sorafenib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          Sorafenib
         </a>
         (Nexavar) is a multitargeted, orally active, small-molecule tyrosine kinase inhibitor that inhibits RAF kinase and also blocks the intracellular portion of the vascular endothelial growth factor receptor (VEGFR). The multicenter, placebo-controlled, European SHARP trial established sorafenib monotherapy as a reference standard systemic treatment for advanced HCC and formed the basis for approval of sorafenib for unresectable HCC in the United States. (See
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma", section on 'Sorafenib'
         </a>
         .)
        </p>
        <p>
         A benefit for adjuvant
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         could not be shown in the international phase III STORM trial, in which 1114 patients undergoing surgical resection or local ablation for localized HCC were randomly assigned to sorafenib (400 mg twice daily) versus placebo [
         <a href="#rid157">
          157
         </a>
         ]. Patients receiving sorafenib did not have better overall survival (HR 0.99, 95% CI 0.76-1.30), time to recurrence (HR 0.89, 95% CI 0.74-1.08), or recurrence-free survival (HR 0.94, 95% CI 0.78-1.13).
        </p>
        <p class="headingAnchor" id="H969404108">
         <span class="h1">
          POST-TREATMENT SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who undergo a complete resection are at risk for disease recurrence and second primary HCC. Most patients who experience recurrence after resection have recurrent disease confined to the liver. The main goal of post-treatment surveillance is early identification of disease that might be amenable to subsequent local therapy. Several effective treatment modalities can provide disease control after recurrence, including repeat hepatectomy, local ablative therapy, liver transplantation, or transarterial chemoembolization or radioembolization.
        </p>
        <p>
         The importance of regular postoperative surveillance can be illustrated by a report of 734 Chinese patients who were alive and free of recurrence two years following resection of HCC; of the 303 who had a subsequent recurrence, outcomes were better for those who had received regular post-treatment surveillance [
         <a href="#rid158">
          158
         </a>
         ]. Potentially curative treatments were more often applied (76 versus 36 percent), and median overall survival was significantly higher (67 versus 20 months, 95% CI 0.224-0.418) in this group. The main risk factors for a late recurrence were male sex, cirrhosis, multiple tumors, satellite nodules, tumor size &gt;5 cm, and the presence of vascular invasion. (See
         <a class="local">
          'Patterns of relapse'
         </a>
         above.)
        </p>
        <p>
         There are few data to guide the optimal post-treatment surveillance strategy in patients undergoing locoregional therapy for HCC.
        </p>
        <p>
         We (and others [
         <a href="#rid68">
          68
         </a>
         ]) suggest the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) every four months for two to three years, then every six months
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assay of serum alpha-fetoprotein (AFP), if initially elevated, every four months for two to three years, then every six months
        </p>
        <p>
        </p>
        <p>
         These recommendations are consistent with consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
         Some have suggested tailoring the CT/MRI surveillance schedule according to recurrence risk in order to reduce cost and exposure to unnecessary radiation [
         <a href="#rid159">
          159
         </a>
         ]. For those with low-risk (no microvascular invasion and no cirrhosis) or intermediate-risk disease (no microvascular invasion but with cirrhosis, or a solitary tumor with microvascular invasion), it may be possible to extend the surveillance intervals to every 12 months after the initial two years, as recurrence detection rates did not significantly differ with the longer surveillance interval. However, interpretation of these data is limited by the small numbers, the primarily hepatitis B virus (HBV)-infected patient population, the lack of a validation cohort, and possible overfitting of the data.
        </p>
        <p>
         It is also important that patients with cirrhosis continue to receive liver-related care, including monitoring for esophageal varices, and treatment of their underlying liver disease, which may have a major impact on long-term survival. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Importance of comprehensive multidisciplinary care'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1364480426">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119333.html" rel="external">
          "Society guideline links: Hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H969404115">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16838.html" rel="external">
          "Patient education: Liver cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H969404122">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. Most patients with HCC need comprehensive multidisciplinary care for proper monitoring and assessment of their disease. (See
         <a class="local">
          'Importance of comprehensive multidisciplinary care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical management
         </strong>
         – Partial hepatectomy is one potentially curative treatment for HCC in patients who have adequate liver reserve. (See
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative evaluation
         </strong>
         – The preoperative evaluation for resection of HCC should focus on two main issues: the likelihood of disease being confined to the liver, and whether the anatomical constraints of the intrahepatic tumor and underlying liver dysfunction will permit resection. (See
         <a class="local">
          'Preoperative evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">
          "Surgical resection of hepatocellular carcinoma", section on 'Preoperative assessment for resectability'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Postoperative outcomes
         </strong>
         – There is wide variability in outcomes after partial hepatectomy for HCC, mostly attributed to patient selection. The best outcomes (five-year survival rates up to 78 percent) after resection are reported in carefully selected patients with intact liver function who have solitary lesions without intrahepatic metastasis or vascular invasion, tumor diameter ≤5 cm, and a negative surgical margin of &gt;1 cm. (See
         <a class="local">
          'Long-term outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Is there a role for neoadjuvant therapy?
         </strong>
         – Given the high rates of local recurrence after hepatic resection, several types of locoregional neoadjuvant therapy have been evaluated prior to resection, including transarterial chemoembolization (TACE), hepatic arterial infusion of radiolabeled lipiodol, and regional irradiation with or without chemotherapy or TACE. Given the lack of survival benefit in most studies, and the heterogeneity of the populations that have been studied using these approaches, we suggest not pursuing neoadjuvant therapy prior to hepatic resection, unless in the context of a clinical trial (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Neoadjuvant therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjuvant antiviral therapy for HCC and hepatitis B or C infection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hepatitis B
         </strong>
         – Adjuvant antiviral therapy improves outcomes after potentially curative treatment of hepatitis B virus (HBV)-related HCC. For patients with HBV-related HCC and active HBV-related liver disease, we recommend the use of nucleos(t)ide analogs (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). The benefits of nucleos(t)ide analogs on oncologic outcomes in resected patients who do not have active hepatitis and/or a high viral load remain uncertain and require confirmation in large controlled trials with adequate follow-up before this approach can be widely adopted. (See
         <a class="local">
          'HBV-related HCC and nucleoside/nucleotide analogs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hepatitis C
         </strong>
         – For patients with hepatitis C virus (HCV)-related HCC, we endorse the use of direct-acting antiviral (DAA) agents used for HCV therapy. A major benefit of HCV antiviral treatment among those with active viral infection is a reduction in liver-disease-related morbidity and mortality. (See
         <a class="local">
          'HCV-related HCC'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">
          "Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Hepatocellular carcinoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Timing of antiviral therapy
         </strong>
         – Although postoperative therapy is pursued at many institutions, data comparing preoperative versus postoperative therapy are extremely limited, and clinical practice is variable, with some preferring preoperative antiviral therapy. In our view, either approach is reasonable. (See
         <a class="local">
          'Timing of antiviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other adjuvant therapies
         </strong>
         – The use of other adjuvant systemic regimens or hepatic arterial infusion (HAI) therapy remains investigational. Patients interested in these approaches are encouraged to enroll in clinical trials, where available. (See
         <a class="local">
          'Investigational approaches'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-treatment surveillance
         </strong>
         – In patients undergoing locoregional therapy for HCC, we agree with the consensus-based guidelines from the National Comprehensive Cancer Network (NCCN), which suggest the following after ablation or resection of HCC (see
         <a class="local">
          'Post-treatment surveillance'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Imaging every three to six months for two to three years, then every 6 to 12 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Assay of serum alpha-fetoprotein (AFP), if initially elevated, every three months for two to three years, then every 6 to 12 months.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gabr A, Abouchaleh N, Ali R, et al. Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2018; 29:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paquet KJ, Koussouris P, Mercado MA, et al. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg 1991; 78:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993; 217:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen MF, Jeng LB. Partial hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozawa K, Takayasu T, Kumada K, et al. Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period. Am J Surg 1991; 161:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009; 249:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995; 22:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nonami T, Harada A, Kurokawa T, et al. Hepatic resection for hepatocellular carcinoma. Am J Surg 1997; 173:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon RT, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001; 19:3037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002; 235:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013; 57:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007; 245:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009; 145:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for hepatocellular carcinoma in diameter of &gt; or = 10 cm. Hepatogastroenterology 2002; 49:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagao T, Inoue S, Goto S, et al. Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg 1987; 205:33.
          </a>
         </li>
         <li class="breakAll">
          Abou-Alfa GK, Pawlik TM, Shindoh J, Vauthey JN. Liver. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.287.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006; 107:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng CH, Lee CF, Wu TH, et al. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol 2011; 9:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010; 116:3006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013; 257:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzaferro V, Roayaie S, Poon R, Majno PE. Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. Ann Surg 2015; 262:e17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruix J, Fuster J. A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group. Ann Surg 2015; 262:e30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker GA, Lawrence W Jr, Horsley JS 3rd, et al. Intraoperative ultrasound of the liver affects operative decision making. Ann Surg 1989; 209:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shindoh J, Andreou A, Aloia TA, et al. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol 2013; 20:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990; 66:2174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu HC, Sheu JC, Lin YH, et al. Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC. Cancer 1985; 56:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon RT, Fan ST, Lo CM, et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001; 136:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shrager B, Jibara GA, Tabrizian P, et al. Resection of large hepatocellular carcinoma (≥10 cm): a unique western perspective. J Surg Oncol 2013; 107:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg 2000; 231:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang SH, Kim DY, Jeon SM, et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol 2012; 24:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanashima A, Taura N, Abo T, et al. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci 2011; 56:3086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwadou S, Nouso K, Kuwaki K, et al. Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Liver Int 2010; 30:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009; 16:2795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou YM, Yang JM, Li B, et al. Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int 2010; 9:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blank S, Wang Q, Fiel MI, et al. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol 2014; 21:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasaki K, Matsuda M, Ohkura Y, et al. Implication of an extremely high preoperative alpha-fetoprotein value (&gt;4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma. Surgery 2015; 157:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu CL, Fan ST, Lo CM, et al. Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol 2001; 19:3725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou L, Rui JA, Wang SB, et al. Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade. Eur J Surg Oncol 2011; 37:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Fiel MI, Blank S, et al. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer 2013; 109:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alkofer B, Lepennec V, Chiche L. Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg 2011; 148:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trevisani F, Frigerio M, Santi V, et al. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnaoutakis DJ, Mavros MN, Shen F, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol 2014; 21:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989; 106:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993; 113:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi TK, Edward CS, Fan ST, et al. Results of surgical resection for hepatocellular carcinoma. Hepatogastroenterology 1990; 37:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Zhou J, Yang PH, et al. Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma. Eur J Cancer 2016; 62:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Lei Z, Xia Y, et al. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg 2018; 153:e182721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roayaie S, Haim MB, Emre S, et al. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol 2000; 7:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao WY, Su CW, Chau GY, et al. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg 2011; 35:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huo TI, Wu JC, Hsia CY, et al. Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas. World J Surg 2004; 28:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chirica M, Tranchart H, Tan V, et al. Infection with hepatitis C virus is an adverse prognostic factor after liver resection for early-stage hepatocellular carcinoma: implications for the management of hepatocellular carcinoma eligible for liver transplantation. Ann Surg Oncol 2013; 20:2405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawlik TM, Poon RT, Abdalla EK, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004; 8:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatzaras I, Bischof DA, Fahy B, et al. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol 2014; 21:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen MF, Hwang TL, Jeng LB, et al. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg 1994; 129:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991; 214:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng J, Chou JF, Gönen M, et al. Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Ann Surg 2017; 266:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon RT. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 2009; 16:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007; 141:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003; 238:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Itamoto T, Nakahara H, Amano H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 2007; 141:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CC, Cheng SB, Yeh DC, et al. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg 2009; 96:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015; 261:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xia Y, Li J, Liu G, et al. Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. JAMA Oncol 2020; 6:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004; 240:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 1996; 224:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998; 15:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchida M, Kohno H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adachi E, Matsumata T, Nishizaki T, et al. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993; 72:3593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KT, Lu YW, Wang SN, et al. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009; 99:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasaki A, Iwashita Y, Shibata K, et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 2006; 32:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brans B, De Winter F, Defreyne L, et al. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001; 16:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Zhong C, Li Q, et al. Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial. J Clin Oncol 2021; 39S: ASCO #4008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitzmann JV. Conversion of unresectable to resectable liver cancer: an approach and follow-up study. World J Surg 1995; 19:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang ZY, Uy YQ, Zhou XD, et al. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients. World J Surg 1995; 19:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei X, Jiang Y, Zhang X, et al. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol 2019; 37:2141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Cancer 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004; 139:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006; 93:1091.
          </a>
         </li>
         <li class="breakAll">
          Imamura H, Seyama Y, Makuuchi M, Kokudo Norihiro. Sequential TACE and PVE for hepatocellular carcinoma. In: Venous Embolization of the Liver, Madoff DC et al (Ed), Spring-Verlag, London 2011. p.249.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi J, Lai EC, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2010; 17:2073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012; 12:e7635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Utsunomiya T, Shimada M, Kudo M, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg 2015; 261:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verslype C, Rosmorduc O, Rougier P, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2017.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim BK, Park JY, Kim DY, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008; 28:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013; 31:3647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg 2015; 261:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun P, Dong X, Cheng X, et al. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One 2014; 9:e102761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308:1906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol 2016; 2016:5234969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong CC, Lai PB. Antiviral therapy after curative resection for patients with hepatitis B-related hepatocellular carcinoma. Br J Surg 2013; 100:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer 2017; 140:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology 2019; 157:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol 2019; 71:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okamura Y, Sugiura T, Ito T, et al. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 2019; 26:4566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konjeti VR, John BV. Interaction Between Hepatocellular Carcinoma and Hepatitis C Eradication With Direct-acting Antiviral Therapy. Curr Treat Options Gastroenterol 2018; 16:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology 2019; 156:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piñero F, Boin I, Chagas A, et al. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence. Liver Transpl 2020; 26:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology 2019; 156:2149.
          </a>
         </li>
         <li class="breakAll">
          NCCN guidelines available online at https://www.nccn.org/professionals/physician_gls/ (Accessed on June 25, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogawa E, Toyoda H, Iio E, et al. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clin Infect Dis 2020; 71:2840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prenner SB, VanWagner LB, Flamm SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017; 66:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beste LA, Green PK, Berry K, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017; 67:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Persico M, Aglitti A, Aghemo A, et al. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther 2018; 47:1705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen LT, Chen MF, Li LA, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ono T, Yamanoi A, Nazmy El Assal O, et al. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001; 91:2378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Mei J, Wang Q, et al. Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial. Ann Surg Oncol 2020; 27:5183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li SH, Mei J, Cheng Y, et al. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. J Clin Oncol 2023; 41:1898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhong JH, Zhong QL, Li LQ, Li H. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumour Biol 2014; 35:9459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhong JH, Ma L, Li LQ. Postoperative therapy options for hepatocellular carcinoma. Scand J Gastroenterol 2014; 49:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labadie KP, Sham JG. Adjuvant Transcatheter Arterial Infusion Therapy for Hepatocellular Carcinoma: Not Yet for Everybody. Ann Surg Oncol 2020; 27:4070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuel M, Chow PK, Chan Shih-Yen E, et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009; :CD001199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res 2010; 40:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhai XF, Liu XL, Shen F, et al. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study. Cancer 2018; 124:2161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai S, Yang P, Liu J, et al. Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE. Oncologist 2023; 28:e633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng X, Sun P, Hu QG, et al. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. J Cancer Res Clin Oncol 2014; 140:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qi X, Liu L, Wang D, et al. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Oncotarget 2015; 6:36838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Z, Ren Z, Chen Y, et al. Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. Clin Cancer Res 2018; 24:2074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okayasu I, Hatakeyama S, Yoshida T, et al. Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery. Am J Clin Pathol 1988; 90:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008; 247:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung AY, Ooi LL, Machin D, et al. Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg 2013; 37:1356.
          </a>
         </li>
         <li class="breakAll">
          Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis (Lipiocis). http://clinicaltrials.gov/ct2/show/NCT00116454 (Accessed on May 17, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu XF, Xing H, Han J, et al. Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China. JAMA Surg 2019; 154:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu D, Fong DY, Chan AC, et al. Hepatocellular carcinoma: surveillance CT schedule after hepatectomy based on risk stratification. Radiology 2015; 274:133.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 17215 Version 60.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30268638" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8831597" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2155591" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1851652" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8385442" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9407354" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Partial hepatic resection for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1650535" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1851588" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19387322" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Predictors of survival after resection of early hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10363892" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : An analysis of 412 cases of hepatocellular carcinoma at a Western center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9794907" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Early hepatocellular carcinoma as an entity with a high rate of surgical cure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2154320" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7650331" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9136782" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hepatic resection for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11408499" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11022927" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11093728" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11981219" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Preoperative predictors of survival after resection of small hepatocellular carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1656903" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hepatic resection versus transplantation for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34801630" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22576353" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Resection of hepatocellular cancer≤2 cm: results from two Western centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17197963" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19303988" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11995486" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hepatic resection for hepatocellular carcinoma in diameter of&gt;or = 10 cm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3026259" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3026259" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16708358" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11896101" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Simplified staging for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21958080" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20564406" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23426336" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24368644" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24374519" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24583061" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2650644" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Intraoperative ultrasound of the liver affects operative decision making.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23179993" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2171748" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2988752" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10694562" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11343543" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11301395" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22903563" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Resection of large hepatocellular carcinoma (≥10 cm): a unique western perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15897440" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749616" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22495400" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21706206" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20492506" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19669841" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20133226" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Risk factors for early recurrence of small hepatocellular carcinoma after curative resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24232510" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25616938" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Implication of an extremely high preoperative alpha-fetoprotein value (&gt;4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11533094" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Management of spontaneous rupture of hepatocellular carcinoma: single-center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21531111" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23846171" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21306970" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Hepatocellular cancer in the non-cirrhotic liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19828388" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23959056" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2799650" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Primary hepatic malignancy: surgical management and determinants of survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8389492" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Postresection prognosis of patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1692802" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Results of surgical resection for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27232330" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30073257" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11129425" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21207029" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15457359" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23338483" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Infection with hepatitis C virus is an adverse prognostic factor after liver resection for early-stage hepatocellular carcinoma: implications for the management of hepatocellular carcinoma eligible for liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15531232" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24006095" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Treatment options and surveillance strategies after therapy for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7517662" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11882759" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1714267" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28650354" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19190964" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17263976" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14578733" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17462458" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Repeat hepatectomy for recurrent hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19672929" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Second and third hepatectomies for recurrent hepatocellular carcinoma are justified.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25010665" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31774468" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15273555" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Salvage surgery following downstaging of unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8678616" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9845635" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8661839" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8252473" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19226530" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7881929" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10947016" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16797156" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11603004" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8553667" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Conversion of unresectable to resectable liver cancer: an approach and follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8553666" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31283409" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249411" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16779884" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16779884" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20131013" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23233865" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25072437" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28130846" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : AASLD guidelines for the treatment of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28130846" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : AASLD guidelines for the treatment of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18028321" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19747749" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24002499" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25072444" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25058587" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23162861" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27446846" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23475744" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Antiviral therapy after curative resection for patients with hepatitis B-related hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27861842" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31374215" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30959157" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31602577" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27349488" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27084592" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26829205" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29569093" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Interaction Between Hepatocellular Carcinoma and Hepatitis C Eradication With Direct-acting Antiviral Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30660729" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32133773" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30878469" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30878469" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31777940" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28161470" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28267622" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29722439" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22104564" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10915728" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11352697" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16557381" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17522506" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133492" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15785093" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14716774" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12585827" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19672926" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37871608" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11413528" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32418078" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36525610" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25119592" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24716523" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Postoperative therapy options for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32529273" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Adjuvant Transcatheter Arterial Infusion Therapy for Hepatocellular Carcinoma: Not Yet for Everybody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19160192" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20887328" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29499082" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37029989" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24752339" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26451613" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29420221" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2459957" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10459961" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18156922" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23463394" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23463394" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26361969" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30422241" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162308" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Hepatocellular carcinoma: surveillance CT schedule after hepatectomy based on risk stratification.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
